About Us

IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.

IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.

Mission

Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.

Discription of Business

  • IPG will conduct non-clinical R&D steps efficiently to create clinical candidates for new drugs, and create intellectual property (e.g., patents) by utilizing not only ADDP’s promising drug seeds, inherited from Takeda Pharmaceutical Company Limited, but also innovative drug discovery concepts of global academic institutions.
  • IPG will license out the new drug candidates to pharmaceutical companies around the world, and monetize them (up-front payment and royalties).
  • IPG membership has been established as a key driver of the above IPG’s business.

Membership

  1. Registered Membership Program
  2. No membership fee
  3. Members can review IPG projects under development by IPG and receive progress reports.
  4. Members can exchange information with IPG on target diseases and drug targets of interest to them and express their willingness to adopt IPG’s projects.

Company Profile

Name of the CompanyIPGaia, Inc.
Location2-5-1 Atago, Minato-ku, Tokyo 105-6236
InvestorHealthcare New Platform Fund(100%)
General Partner; Whiz Partners Inc.
Capital and Capital Reserves10 million JPY
EstablishedOctober 26th, 2021
Business Scope
  1. R&D and sales of pharmaceuticals
  2. Business in increasing the value of intellectual property and selling usage rights
  3. All other businesses incidental and related to the above
ManagementPresident & CEO
Chairman
Yasunori Yamaguchi
Satoru Iino

Press Release

Press Release

IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement

IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) have entered into a Comprehensive Collaborative Research and Development Agreement (“this agreement”) dated August 7th, 2024. This agreement establishes a formal framework for the incorporation of promising drug target leads from Icahn Mount Sinai into IPG’s drug discovery platform. This agreement enables Icahn Mount Sinai to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of research institutions, including global academia and pharmaceutical companies, …

IPGaia Announce Master Collaborative Research and Development Agreement with Tohoku University

IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) has entered into a Master Collaborative Research and Development Agreement (“this agreement”) with Tohoku University. This agreement is intended to propose drug discovery seeds handled by Tohoku University Hospital (Sendai, Miyagi Prefecture, Japan; Hospital Director: Hideo Harigae, “Tohoku University Hospital”)※1, regarding IPG platform for efficient generation of high-quality new drugs. This agreement enables IPG to receive proposals for drug discovery seeds handled by Tohoku University Hospital. IPG pursues the joint research program with Tohoku University for identification and development of clinical development candidates with the goal of licensing them to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of …

IPGaia, Inc. Announces Master Collaborative Research and Development Agreement with Weill Cornell Medicine-Qatar

IPGaia, Inc (IPG) has entered an agreement to collaborate with researchers at Weill Cornell Medicine-Qatar (WCM-Q) to investigate promising targets for the development of new medicines. The Master Collaborative Research and Development Agreement was signed in October 2023 by IPG and Cornell University, based in Ithaca, New York, USA. WCM-Q, based in Doha, is a location of Weill Cornell Medicine in New York, which is part of Cornell University. The Master Agreement establishes a formal framework for the incorporation of promising drug target leads discovered at WCM-Q into IPG’s drug discovery platform.   The agreement enables WCM-Q to propose drug targets to IPG for identification and development of lead compounds …